Evidence map›Paper›PMID 25348513›Full record

SynthesisClinical cancer research : an official journal of the American Association for Cancer Research2015

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.

Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 16 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 16 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Pooled it
  7. Pooled it
  8. Hormone replacement therapy after surgery for epithelial ovarian cancer.The Cochrane database of systematic reviews · 2020
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Article
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Qian ZhongDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, PR China.
Hong-Ling PengDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, PR China.
Xia ZhaoDepartment of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, PR China.
Lin ZhangOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania. whwang@mail.med.upenn.edu linzhang@mail.med.upenn.edu.
Wei-Ting HwangOvarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania. whwang@mail.med.upenn.edu linzhang@mail.med.upenn.edu.
Sichuan University · CNUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Therapeutic Micro RNA Strategies for Ovarian CancerP50CA083638 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI GODWIN, ANDREW K., GOLEMIS, ERICA A. · 1999 to 2013
$33.6M
The role of microRNA, mir-30d, in the initiation and progression of cancerR01CA142776 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ZHANG, LIN · 2010 to 2014
$1.6M
NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA083638NCI NIH HHS P50-CA83638NCI NIH HHS R01 CA142776NCI NIH HHS R01-CA142776
6 · The paper itself

Abstract

purposeTo estimate the effects of BRCA1 and BRCA2 mutations on ovarian cancer and breast cancer survival. EXPERIMENTAL

designWe searched PubMed and EMBASE for studies that evaluated the associations between BRCA mutations and ovarian or breast cancer survival. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and progression-free survival (PFS).

resultsFrom 1,201 unique citations, we identified 27 articles that compared prognosis between BRCA mutation carriers and noncarriers in patients with ovarian or breast cancer. Fourteen studies examined ovarian cancer survival and 13 studies examined breast cancer survival. For ovarian cancer, meta-analysis demonstrated that both BRCA1 and BRCA2 mutation carriers had better OS (HR, 0.76; 95% CI, 0.70-0.83 for BRCA1 mutation carriers; HR, 0.58; 95% CI, 0.50-0.66 for BRCA2 mutation carriers) and PFS (HR, 0.65; 95% CI, 0.52-0.81 for BRCA1 mutation carriers; HR, 0.61; 95% CI, 0.47-0.80 for BRCA2 mutation carriers) than noncarriers, regardless of tumor stage, grade, or histologic subtype. Among patients with breast cancer, BRCA1 mutation carriers had worse OS (HR, 1.50; 95% CI, 1.11-2.04) than noncarriers but were not significantly different from noncarriers in PFS. BRCA2 mutation was not associated with breast cancer prognosis.

conclusionsOur analyses suggest that BRCA mutations are robust predictors of outcomes in both ovarian and breast cancers and these mutations should be taken into account when devising appropriate therapeutic strategies.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDisease-Free SurvivalFemaleHumansMutationOvarian NeoplasmsPrognosisSurvivalBRCA1 ProteinBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID25348513
PMCPMC4286460
OpenAlexW2096253955

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.